Systemic XXXX + cells can predict pregnancy outcome.

@entity1 @entity2208 @entity249 @entity6677 @entity2940 @entity4810
PROBLEM: To evaluate differences in circulating @entity2940 + cells between successful and unsuccessful pregnancies, 114 pregnant @entity1 were studied prospectively. METHOD: Seventy @entity1 had a history of @entity249 ( @entity249 ) and 44 had two or more @entity2208 (RSA). Among the @entity249 @entity1 , 12 were donor egg recipients (DER) and 15 underwent intracytoplasmic sperm injection (ICSI) for treatment of @entity4810 . Nineteen @entity1 were carrying @entity6677 ( @entity6677 ) and 55 had singleton gestations (SG). Thirteen additional @entity1 were receiving intravenous immunoglobulin (IVIg). RESULTS: The percentage of @entity2940 + cells was determined in 310 blood samples from 114 pregnant @entity1 by flow cytometry. The prevalence of @entity1 with persistent elevation of percent of 56+ cells (> 12%) was 58% among DER, 73% among ICSI, 37% among @entity6677 , 22% among SG, 18% among RSA, and 39% among @entity249 . Thirteen @entity1 with SG received IVIG, 10 had @entity2940 + cells greater than 12% and all 13 experienced live births. @entity1 with percentage @entity2940 + cells persistently greater than 12% who were not DER, not ICSI, not receiving IVIg, and not carrying @entity6677 had a live birth rate of 11%. @entity1 with greater than 12% @entity2940 + cells had normal karyotype in 78% of concepti studied in contrast to @entity1 less than 12% @entity2940 + cells who had 68% abnormal karyotypes (P = 0.04). CONCLUSION: Elevated @entity2940 + cells in pregnant @entity1 who are not DER, not ICSI, not receiving IVIg, and not carrying @entity6677 predicts loss of a karyotypically normal conceptus with a specificity of 87% and positive predictive value of 78%. While the specificity value of this test is high in both @entity249 and RSA populations, the sensitivity is 86% in RSA and only 54% in @entity249 suggesting this test does not identify all losses among @entity249 . It may identify a subset of pregnancies at risk for loss of a karyotypically normal embryo that may respond to treatment with IVIg.
